Abstract
Belantamab mafodotin (BLENREP™; belantamab mafodotin-blmf) is a first-in-class monoclonal antibody-drug conjugate (ADC) that has been developed for the treatment of multiple myeloma by GlaxoSmithKline. The ADC comprises an antibody targeting B-cell maturation antigen (BCMA) conjugated to the microtubule inhibitor monomethyl auristatin F (MMAF). The antibody moiety binds to BCMA on the tumour cell surface, delivering the cytotoxic microtubule inhibitor MMAF to the therapeutic target. Based on preliminary results from the multinational DREAMM-2 trial, belantamab mafodotin was approved in early August 2020 in the USA for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapies, including an anti CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. The ADC was also approved in the EU for this indication in late August 2020. This article summarizes the milestones in the development of belantamab mafodotin leading to this first approval.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
GlaxoSmithKline. GSK announces FDA advisory committee votes in favour of positive benefit/risk profile for belantamab mafodotin for patients with relapsed/refractory multiple myeloma [media release]. 14 Jul 2020. https://www.gsk.com.
GlaxoSmithKline. BLENREP (belantamab mafodotin-blmf): US prescribing information. 2020. https://www.accessdata.fda.gov/. Accessed 7 Aug 2020.
BioWa Inc. BioWa announces licensing of BioWa′s POTELLIGENT(R) technology by GlaxoSmithkline for use in antibody research and development. [media release]. 19 Oct 2007. http://www.biowa.com.
Seattle Genetics. Seattle Genetics announces antibody-drug conjugate collaboration with GlaxoSmithKline [media release]. 22 Dec 2009. http://www.seattlegenetics.com.
GlaxoSmithKline. Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/ refractory multiple myeloma [media release]. 16 Dec 2019. https://www.gsk.com.
US Food and Drug Administration. FDA granted accelerated approval to belantamab mafodotin-blmf for multiple myeloma [media release]. 5 Aug 2020. https://www.fda.gov/.
European Medicines Agency (EMA). BLENREP (belantamab mafodotin): EU summary of product characteristics. 2020. https://ec.europa.eu/health/documents/community-register/2020/20200825148987/anx_148987_en.pdf. Accessed 1 Sep 2020.
SpringWorks Therapeutics. SpringWorks Therapeutics announces global clinical collaboration with GlaxoSmithKline to evaluate nirogacestat in combination with belantamab mafodotin in patients with relapsed or refractory multiple myeloma [media release]. 27 Jun 2019. http://www.springworkstx.com.
Tai Y-T, Mayes PA, Acharya C, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123(20):3128–38.
Ferron-Brady G, Rathi C, Collins J, et al. Therapeutic dose selection for belantamab mafodotin, a BCMA-targeting agent, in patients with relapsed/refractory multiple myeloma (RRMM): application of population pharmacokinetics (PopPK) and exposure-response (E-R) analyses [abstract no. CT196]. In: 111th Annual Meeting of the American Association for Cancer Research-I. 2020.
Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2019;21:207–21.
Lonial S, Lee HC, Badros A, et al. Pivotal DREAMM-2 study: single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) refractory to proteasome inhibitors (PIs), immunomodulatory agents, and refractory and/or intolerant to anti-cd38 monoclonal antibodies (mAbs) [abstract no. EP970 and poster]. In: 25th European Hematology Association (EHA) Congress, Virtual Format. 2020.
Nooka AK, Manteca MVM, Bahlis N, et al. DREAMM-4: Evaluating safety and clinical activity of belantamab mafodotin in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM) [abstract no. EP955 plus poster]. In: 25th European Haematology Association (EHA) Congress, Virtual Format. 2020.
Popat R, Stockerl-Goldstein K, Quach H, et al. DREAMM-6: safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma [abstract no. EP1031 plus poster]. In: 25th European Hematology Association (EHA) Congress, Virtual Format. 2020.
Trudel S, Lendvai N, Popat R, et al. Antibody-drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019;9(4):37.
Richardson PG, Biswas S, Holkova B, et al. DREAMM-5 platform trial: belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM) [abstract no. TPS8552]. In: 56th Annual Meeting of the American Society of Clinical Oncology. 2020.
Weisel K, Strauss J, Moreau P, et al. DREAMM-3: phase III, open-label, randomized study of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone (Pom/Dex) in relapsed/refractory multiple myeloma (RRMM) [abstract no. PB2041]. In: 25th European Haematology Association (EHA) Congress. 2020.
GlaxoSmithKline. GSK announces further positive data from DREAMM-1 study of anti-BCMA antibody-drug conjugate in patients with relapsed/refractory multiple myeloma [media release]. 21 Mar 2019. https://www.gsk.com.
Usmani SZ, Terpos E, Janowski W, et al. DREAMM-9: phase III study of belantamab mafodotin plus VRd versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma (TI NDMM) [abstract no. TPS8556]. In: 56th Annual Meeting of the American Society of Clinical Oncology. 2020.
GlaxoSmithKline. GSK announces new data presentations from the DREAMM programme exploring investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma [media release]. 4 Jun 2020. https://www.gsk.com/.
Acknowledgements
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest
A. Markham is a contracted employee of Adis International Ltd/Springer Nature, is responsible for the article content and declares no relevant conflicts of interest.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability
Not applicable.
Additional information
Enhanced Material
for this AdisInsight Report can be found at https://doi.org/10.6084/m9.figshare.12903962.
This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.
Rights and permissions
About this article
Cite this article
Markham, A. Belantamab Mafodotin: First Approval. Drugs 80, 1607–1613 (2020). https://doi.org/10.1007/s40265-020-01404-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-020-01404-x